Excision BioTherapeutics

| founders = {{Unbulleted list

| founders = {{Unbulleted list

| Kamel Khalili

| Kamel Khalili

| Tom Malcolm

David Rowe

Rob Simmons

'''Excision BioTherapeutics''' is a [[biopharmaceutical]] company based in San Francisco focused on developing [[Gene therapy|gene therapies]] against HIV infection.

'''Excision BioTherapeutics''' is a [[biopharmaceutical]] company based in San Francisco focused on developing [[Gene therapy|gene therapies]] against HIV infection.

The company has a single, [[CRISPR gene editing|CRISPR–Cas9]] based therapy, EBT-101, under investigation. Initial investigation into the therapy was conducted by the lab of Kamel Khalili, a professor at [[Temple University]].{{cite journal |last1=Sheldon|first1=Cormac|date=30 October 2023|title=Armed with gene technologies and CAR-Ts, scientists are attempting to eliminate viruses that escape immune detection and lurk in tissues for years.|url=https://www.nature.com/articles/s41587-023-02022-0|journal=[[Nature Medicine]]|volume= 41|issue= 11|pages= 1491–1493|doi=10.1038/s41587-023-02022-0|pmid=37903922 |s2cid=264673741 |access-date=16 November 2023|url-access=subscription}}{{cite news |last= |first= |date=27 January 2023|title=The first human study has launched to treat HIV patients with CRISPR. The CEO of the gene-editing startup, Daniel Dornbusch, says it could be a one-time cure.|url=https://www.businessinsider.com/excision-starts-crispr-gene-editing-trial-for-hiv-patients-2022-1|work=[[Business Insider]]|location= |access-date=16 November 2023}}{{cite news |last=Brzyski|first=Laura|date=5 March 2023|title=Excision BioTherapeutics Has Secured $60M to Proceed with HIV Clinical Trial|url=https://www.phillymag.com/healthcare-news/2021/03/05/excision-biotherapeutics-temple-hiv-clinical-trial/|work=[[Philadelphia (magazine)|Philadelphia]]|location= |access-date=16 November 2023}}{{cite news |last=Krieger|first=Lisa|date=28 October 2023|title=CRISPR gene editing could kill HIV. But is it a cure?|url=https://www.mercurynews.com/2023/10/28/crispr-could-kill-hiv-but-is-it-a-cure/|work=[[The Mercury News]]|location= |access-date=16 November 2023}} In July 2023 the US [[Food and Drug Administration]] granted EBT-101 [[Fast track (FDA)|fast-track]] status.{{cite news |last=Leuty|first=Ron|date=21 July 2023|title=S.F. biotech inches closer to potential HIV cure with key move by FDA|url=https://www.bizjournals.com/sanfrancisco/news/2023/07/20/hiv-aids-cure-crispr-jennifer-doudna-excision.html|work=[[San Francisco Business Times]]|location= |access-date=17 November 2023}} In October 2023 an early-stage study on 3 people reported that the treatment appeared to be safe with no major side effects.{{Cite web |title=Three people were gene-edited in an effort to cure their HIV. The result is unknown. |url=https://www.technologyreview.com/2023/10/25/1082306/gene-editing-crispr-hiv-experiment/ |access-date=2024-03-20 |website=MIT Technology Review |language=en}} In March 2024 it was revealed that EBT-101 did not maintain HIV viral suppression when used alone at the initial dose tested, although it might have delayed viral rebound in one trial participant. One possible explanation for the viral rebound is that EBT-101 did not reach all of the cells that harboured latent HIV.

The company has a single, [[CRISPR gene editing|CRISPR–Cas9]] based therapy, EBT-101, under investigation. Initial investigation into the therapy was conducted by the lab of Kamel Khalili, a professor at [[Temple University]].{{cite journal |last1=Sheldon|first1=Cormac|date=30 October 2023|title=Armed with gene technologies and CAR-Ts, scientists are attempting to eliminate viruses that escape immune detection and lurk in tissues for years.|url=https://www.nature.com/articles/s41587-023-02022-0|journal=[[Nature Medicine]]|volume= 41|issue= 11|pages= 1491–1493|doi=10.1038/s41587-023-02022-0|pmid=37903922 |s2cid=264673741 |access-date=16 November 2023|url-access=subscription}}{{cite news |last= |first= |date=27 January 2023|title=The first human study has launched to treat HIV patients with CRISPR. The CEO of the gene-editing startup says it could be a one-time cure.|url=https://www.businessinsider.com/excision-starts-crispr-gene-editing-trial-for-hiv-patients-2022-1|work=[[Business Insider]]|location= |access-date=16 November 2023}}{{cite news |last=Brzyski|first=Laura|date=5 March 2023|title=Excision BioTherapeutics Has Secured $60M to Proceed with HIV Clinical Trial|url=https://www.phillymag.com/healthcare-news/2021/03/05/excision-biotherapeutics-temple-hiv-clinical-trial/|work=[[Philadelphia (magazine)|Philadelphia]]|location= |access-date=16 November 2023}}{{cite news |last=Krieger|first=Lisa|date=28 October 2023|title=CRISPR gene editing could kill HIV. But is it a cure?|url=https://www.mercurynews.com/2023/10/28/crispr-could-kill-hiv-but-is-it-a-cure/|work=[[The Mercury News]]|location= |access-date=16 November 2023}} In July 2023 the US [[Food and Drug Administration]] granted EBT-101 [[Fast track (FDA)|fast-track]] status.{{cite news |last=Leuty|first=Ron|date=21 July 2023|title=S.F. biotech inches closer to potential HIV cure with key move by FDA|url=https://www.bizjournals.com/sanfrancisco/news/2023/07/20/hiv-aids-cure-crispr-jennifer-doudna-excision.html|work=[[San Francisco Business Times]]|location= |access-date=17 November 2023}} In October 2023 an early-stage study on 3 people reported that the treatment appeared to be safe with no major side effects.{{Cite web |title=Three people were gene-edited in an effort to cure their HIV. The result is unknown. |url=https://www.technologyreview.com/2023/10/25/1082306/gene-editing-crispr-hiv-experiment/ |access-date=2024-03-20 |website=MIT Technology Review |language=en}} In March 2024 it was revealed that EBT-101 did not maintain HIV viral suppression when used alone at the initial dose tested, although it might have delayed viral rebound in one trial participant. One possible explanation for the viral rebound is that EBT-101 did not reach all of the cells that harboured latent HIV.

As of 2024 it has not been disclosed what the future holds for EBT-101, and whether or not dosing will continue in the Phase 1/2 trial. A long-term follow-up study of HIV-1 infected adults who received EBT-101 was also started.

As of 2024 it has not been disclosed what the future holds for EBT-101, and whether or not dosing will continue in the Phase 1/2 trial. A long-term follow-up study of HIV-1 infected adults who received EBT-101 was also started.